Table 1.

Leading Atypical Antipsychotics for the Treatment of Schizophrenia Patients in the U.S.⁶

Drug Developer	Brand	Primary Indication	U.S. Launch	Primary Patent or Exclusivity Expiry
Aripiprazole Otsuka	Abilify	Schizophrenia in adults and adolescents (ages 13–17 years); agitation associated with schizophrenia	2002	April 2015
	Abilify Maintena	Schizophrenia in adults	2013	October 2024
Aripiprazole lauroxil Alkermes	Aristada	Schizophrenia in adults	2015	October 2033
Asenapine Organon/Merck	Saphris	Schizophrenia in adults	2009	October 2026
Brexipiprazole Otsuka/Lundbeck	Rexulti	Schizophrenia in adults	2015	February 2027
Cariprazine Allergan	Vraylar	Schizophrenia	2016	December 2028
Clozapine Novartis	Clozaril	Treatment-resistant schizophrenia; reduction in risk of recurrent suicidal behavior in schizophrenia and schizoaffective disorder	1989	Numerous generics
Iloperidone Vanda	Fanapt	Schizophrenia in adults	2010	November 2016
Lurasidone Dainippon Sumitomo	Latuda	Schizophrenia in adults	2011	July 2018
Olanzapine Lilly	Zyprexa	Schizophrenia in adults and adolescents (ages 13–17 years); agitation associated with schizophrenia	1996	October 2011
Olanzapine pamoate Lilly	Zyprexa Relprevv	Schizophrenia in adults	2009	September 2018
Paliperidone Janssen	Invega	Schizophrenia in adults and adolescents (ages 12–17 years)	2006	April 2012
Paliperidone palmitate Janssen	Invega Sustenna	Schizophrenia in adults	2009	May 2019
	Invega Trinza	Schizophrenia in adults after receiving Invega Sustenna for four months	2015	May 2018
Quetiapine AstraZeneca/Astellas	Seroquel	Schizophrenia in adults and adolescents (ages 13–17 years)	1997	March 2012
	Seroquel XR	Schizophrenia in adults and adolescents (ages 13–17 years)	2007	November 2017
Risperidone Janssen	Risperdal	Schizophrenia in adults and adolescents (ages 13–17 years)	1994	June 2008
	Risperdal Consta	Schizophrenia in adults	2003	2023
Ziprasidone Pfizer	Geodon	Schizophrenia in adults; agitation associated with schizophrenia	2001	March 2012